Clinical Trial

A Study of ART105 in Healthy Adult Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if ART105 is safe in healthy adult participants. It will also learn about the PK and PD profiles of ART105. The main questions it aims to answer are: Is ART105 safe and tolerable in adult participants? How does the ART105 influence the urine PC1 level of participants? Participants will: recieve single dose of ART105 and visit the clinic 3 months
Trial Details
NCT Number NCT07748026
Lead Sponsor Arnatar Therapeutics, Inc.
Conditions Healthy
Enrollment 24 participants
Start Date 2026-08-03
Primary Completion 2027-02-25 (estimated)
Study Completion 2027-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-05